Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in cone photoreceptor cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4792
Sealed predictions
- DPYSL5 in oligodendrocytes, braak-0.42 (p 0.266) → -0.12 (p 0.749)receipt 4799
- DPYSL5 in dopamine neurons, braak+0.34 (p 0.375) → -0.04 (p 0.909)receipt 4800
Swarm cases
receipt 4800: DPYSL5 in dopamine neurons, braak
- power
- full sample +0.03 (p 0.915, n 18), 95% CI -0.45 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.962, n 18). could be the mix.
- skeptic
- leave-one-out range -0.07 to +0.18, sign flips 7; without severely affected donors +0.03 (p 0.915, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DPYSL5 in dopamine neurons.
case closed: nothing better to follow up.
receipt 4799: DPYSL5 in oligodendrocytes, braak
- power
- full sample -0.24 (p 0.328, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.26 (p 0.289, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.29 (p 0.239, n 18). could be the mix.
- skeptic
- leave-one-out range -0.34 to -0.15, sign flips 0; without severely affected donors -0.24 (p 0.328, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DPYSL5 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts